ProQR Q2 revenue more than doubles
PRQR•Analyst view
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell".
The average consensus recommendation for the biotechnology and medical research peer group is "buy".
Wall Street's median 12-month price target for ProQR Therapeutics N.V. is $9.00, about 383.9% above its August 12 closing price of $1.86.
Pipeline outlook
The company expects the full Phase 1 AX-0810 dataset to be presented at a scientific conference later in 2026.
ProQR anticipates initial AX-0811 Phase 1 data by year-end 2026, pending regulatory authorization.
Initial clinical data from biliary atresia and other pipeline programs are expected in the first half of 2027.
Q2 revenue and loss
ProQR Therapeutics N.V.'s second-quarter revenue more than doubled and beat analyst expectations, while the company's net loss narrowed from a year earlier.
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | Beat | EUR 8.76 mln | EUR 4.58 mln (5 Analysts) |
| Q2 Loss Per Share | EUR 0.08 | ||
| Q2 Net Loss | EUR 8.73 mln | ||
| Q2 Loss Per Basic Share | EUR 0.08 | ||
| Q2 Operating Income | -EUR 8.82 mln |
